JOEL O'CONNOR: Open Payments
NPI 1790403988 · MANDEVILLE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,163 in 64 payments from 11 companies in 2025. Trend: 2023 $1,183 · 2024 $1,047 · 2025 $1,163
Food & beverage: $1,163
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 22 | $473 |
| Axsome Therapeutics, Inc. | 13 | $179 |
| ABBVIE INC. | 11 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $144 |
| Neurocrine BioSciences, Inc. | 2 | $59 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $38 |
| Vanda Pharmaceuticals Inc. | 1 | $29 |
| Supernus Pharmaceuticals, Inc. | 1 | $29 |
| Almatica Pharma LLC | 1 | $22 |
| Corium, LLC | 1 | $21 |
Products named: CAPLYTA, Auvelity, VRAYLAR, TRINTELLIX, INGREZZA, FANAPT, Qelbree, LOREEV XR.
Industry payments across LA — which companies pay providers there.
